Company Snapshot: Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. The company’s lead product candidate, Omadacycline, is a novel investigational antibiotic with both once-daily intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), acute bacterial skin and skin structure infections (ABSSSI), and urinary tract infections (UTI). A modernized tetracycline, omadacycline is specifically designed to overcome tetracycline resistance and exhibits activity across a broad spectrum of bacteria, including Gram-positive, Gram-negative, anaerobes, atypical bacteria, and other drug-resistant strains.
- Oct 4 2018 Paratek Announces Acceptance of European Marketing Authorization Application for Oral and Intravenous Omadacycline
- Oct 3 2018 Paratek Pharmaceuticals, Inc. to Host Investor Day on October 23, 2018
- Oct 2 2018 Paratek Announces FDA Approval of NUZYRA™ (Omadacycline)
- Oct 2 2018 FDA Approves SEYSARA™ (Sarecycline) for the Treatment of Moderate to Severe Acne